


Supplementary figure S1

(a)




Supplementary Figure S1. IP with anti Trim24


Whole cell protein extract was generated from ESCs and subjected to co-IP assay followed by western blot analysis. Antibodies are indicated in figure.

Supplementary figure S2

(a) Detailed results of RT-qPCR in fig 3a



(b) Detailed results of ChIP in fig 3b




Supplementary Figure S2. RT-qPCR and ChIP on ERVs


(a) ERV RNA expression was measured using RT-qPCR on ESCs expressing shRNA targeting either Trim24, Trim33 or Scrambled sequence as control. Ct values were normalized to UBC control gene and to WT ESC. Control PCR reactions lacking cDNA (no RT) were below detection in all cases. (N>3) (b) ChIP-based measurement of H3K9me3 with primers specific for different transposable elements, mainly ERVs. Positive control gene (Polrmt) gave the expected results. Graphs show the mean enrichment \pm SEM from two independent experiments relative to the total input samples and normalized to the signal of negative control (Aprt). Statistical significance determined using the Holm-Sidak method, with alpha = 0.05. The results are summarized in Figure 3.

Supplementary figure S3

(a)




(b)



Supplementary Figure S3. NIH3T3 control and copy number of MLV infection

- (a) NIH3T3 cells infected by exogenous MLV containing a GFP reporter, either PBS-P or PBS-Q. Percentage of cell expressing the GFP reporter was measured using a flow cytometer. This results were used to normalize GFP expression for the results described in Figure 4a.
- (b) Analysis of proviral DNA copy number in the indicated cell lines as determined by qPCR.

Supplementary figure S4



Supplementary Figure S4. Bisulfite analysis of proviral DNA

Bisulfite analysis was carried out on the unique 40nt region of the MLV vector, and the results of individual molecules are shown for WT and KD ESC lines, and differentiated NIH3T3 cells as control. The map indicates the relative position of the tested sites. The results are summarized in Figure 4c.

Table S1: Primer list:

Target	F/R	sequence	application
UBC	F	CAGCCGTATATCTTCCCAGACT	RT-qPCR
UBC	R	CTCAGAGGGATGCCAGTAATCTA	RT-qPCR
Oct4	F	AACCAACTCCCGAGGAGTCCA	RT-qPCR
Oct4	R	TCTTCTGCTTCAGCAGCTGGCA	RT-qPCR
Trim24	F	CTGCACCAGCTTGAGAGTCTT	RT-qPCR
Trim24	R	AGCCACTTCCTGCTGTTGTT	RT-qPCR
Trim28	F	CTGCACCAGCTTGAGAGTCTT	RT-qPCR
Trim28	R	AGCCACTTCCTGCTGTTGTT	RT-qPCR
Trim33	F	CAGGTGAAGGTCAAGCAGGA	RT-qPCR
Trim33	R	AGGACTGCTAACATACAGGC	RT-qPCR
Polrmt	F	AGACACCTGCTGCCCTATGT	ChIP
Polrmt	R	GCTCCATCCCAGTGCTTTAC	ChIP
APRT	F	GGGATATCTGCCCTCTT	ChIP/Copy number
APRT	R	CACTCGCCTGCGATGTAGT	ChIP/Copy number
Gapdh	F	ATCCTGTAGGCCAGGTGATG	ChIP/Copy number
Gapdh	R	AGGCTCAAGGGCTTTAAGG	ChIP/Copy number
40nt LTR	F	CCTCCACACACCATACTCA	ChIP/Copy number
40nt LTR	R	CCTGTTGGCCCATATTCA	ChIP/Copy number
PBS_MLV	F	TGGCCAGCAACTTATCTGTG	ChIP/Copy number
PBS_MLV	R	CAGGCGCATAAAATCAGTCA	ChIP/Copy number
GFP	F	AGCTGAAGGGCATCGACTT	ChIP/Copy number
GFP	R	GATGCCGTTCTCTGCTTGT	ChIP/Copy number
MMERGLN	F	CGTAAGGACCCTAGTGGCTG	ChIP/RT-qPCR
MMERGLN	R	GCACTCACTCTTCTCACTCTG	ChIP/RT-qPCR
MLV	F	GTAAAAACTCCACACTCGGC	ChIP/RT-qPCR
MLV	R	ACGATTGGATGCAAACAGC	ChIP/RT-qPCR
RLTR4	F	CATACTCTGCCCAAGCTAA	ChIP/RT-qPCR
RLTR4	R	CAGTAATCGGTGGTGAGGTC	ChIP/RT-qPCR
VL30int	F	TCAACAGGCCAGATGTATTGC	ChIP/RT-qPCR
VL30int	R	ACAAAATGGGAGGGGAAAT	ChIP/RT-qPCR
VL30u3i	F	AGATGTATTGCCAACACAGG	ChIP/RT-qPCR
VL30u3i	R	AGGGGGATGGGAGGGAA	ChIP/RT-qPCR
VL30u3ii	F	GAACCTCCCTCACCCAGA	ChIP/RT-qPCR
VL30u3ii	R	GAGGAGGAGTCAGGAATGC	ChIP/RT-qPCR
VL30u3iii	F	CTTTCACCCCCAAACTCCTC	ChIP/RT-qPCR
VL30u3iii	R	CATCACTAGGGAGTTCTGCCA	ChIP/RT-qPCR
VL30u3iv	F	CCTCAAAATGACATTGCCAA	ChIP/RT-qPCR
VL30u3iv	R	TTTCACAGGCTTATAGAAAACTC	ChIP/RT-qPCR

Table S1: Primer list (continued):

Target	F/R	sequence	application
IAP 5UTR	F	CGGGTCGCGGTAAATAAAGGT	ChIP/RT-qPCR
IAP 5UTR	R	ACTCTCGTCCCCAGCTGAA	ChIP/RT-qPCR
IAP1	F	CGTGAGAACGCGTCAATAA	ChIP/RT-qPCR
IAP1	R	TTCTGGTTCTGGAATGAGGG	ChIP/RT-qPCR
IAP1-Mm_I	F	CTACCTGTGGACGTTGCCTT	ChIP/RT-qPCR
IAP1-Mm_I	R	CATCCATCTGCCACACCTGT	ChIP/RT-qPCR
IAP5	F	GTGCGGTCAAGTCCTACGTAA	ChIP/RT-qPCR
IAP5	R	CCCGGAGCAGAAGTGAAAGT	ChIP/RT-qPCR
IAPLTR1	F	CAGTGCAGACTCATTCAT	ChIP/RT-qPCR
IAPLTR1	R	CTCGGCTCCTCAAAGACTG	ChIP/RT-qPCR
IAPLTR3	F	GGCAAACCTCAGAAGGACAG	ChIP/RT-qPCR
IAPLTR3	R	CACATCTGCCCCATAGGT	ChIP/RT-qPCR
IAPLTR4	F	CAGCTGAAAGGCACAGACAA	ChIP/RT-qPCR
IAPLTR4	R	AAATAGGATCCGGGCCATAC	ChIP/RT-qPCR
IAP-D	F	TGAGAGAGGAGCGATCCAA	ChIP/RT-qPCR
IAP-D	R	GACTGTCGGCTATGCTCTCC	ChIP/RT-qPCR
IAPEYI	F	TTGGTGGGCCACTCACTAAT	ChIP/RT-qPCR
IAPEYI	R	GTGGAGCTCAGCCATGTCA	ChIP/RT-qPCR
IAPEy3	F	TGGTGTGGAAGATGCTGACC	ChIP/RT-qPCR
IAPEy3	R	CCCATCTCTGTCGCCATT	ChIP/RT-qPCR
IAPEz	F	GCTCCTGAAGATGTAAGCAATAAG	ChIP/RT-qPCR
IAPEz	R	CTTCCTTGCAGTCCCGAG	ChIP/RT-qPCR
MMERVK10C	F	CAAATAGCCCTACCATATGTCAG	ChIP/RT-qPCR
MMERVK10C	R	GTATACTTCTTCAGGTCCAC	ChIP/RT-qPCR
ETn-MusD	F	GTGCTAACCCAACGCTGGTC	ChIP/RT-qPCR
ETn-MusD	R	CTCTGGCCTGAAACAACTCCTG	ChIP/RT-qPCR
RLTR45	F	TGCTTTCCGACATGGTAAT	ChIP/RT-qPCR
RLTR45	R	AGTAACCTGACCTGCTCCT	ChIP/RT-qPCR
MERVL	F	ATCTCCTGGCACCTGGTATG	ChIP/RT-qPCR
MERVL	R	AGAAGAAGGCATTGCCAGA	ChIP/RT-qPCR
MuLV	F	GGCAGCCATACATACAGACC	ChIP/RT-qPCR
MuLV	R	TGGTCTGCATAGAACAGCA	ChIP/RT-qPCR
LINE1	F	GATTACCAGATGGCGAAAGG	ChIP/RT-qPCR
LINE1	R	AGTGCTCGTTCTGATGATG	ChIP/RT-qPCR
bis40nt(88)	F	GTT ATT TTG TAA GGT ATG GAA AAA	Bisulfite sequencing
bis40nt(727)	R	ACA AAC ACA AAT AAA TTA CTA ACC A	Bisulfite sequencing
bis40nt(382)	F	GAA ATG ATT TTG TGT TTT ATT TGA A	Bisulfite sequencing
bis40nt(715)	R	AAA TTA CTA ACC AAC TTA CCT CCC	Bisulfite sequencing